These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16949998)

  • 1. Chapter 13: Current findings from prophylactic HPV vaccine trials.
    Koutsky LA; Harper DM
    Vaccine; 2006 Aug; 24 Suppl 3():S3/114-21. PubMed ID: 16949998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HPV vaccination: principles, results and future perspectives].
    Rouzier R; Uzan C; Collinet P
    J Gynecol Obstet Biol Reprod (Paris); 2007 Feb; 36(1):13-8. PubMed ID: 17293248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines.
    Hildesheim A; Markowitz L; Avila MH; Franceschi S
    Vaccine; 2006 Aug; 24 Suppl 3():S3/227-32. PubMed ID: 16950011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protecting our patients from HPV and HPV-related diseases: the role of vaccines.
    Mahoney MC
    J Fam Pract; 2006 Nov; Suppl():10-7. PubMed ID: 17366753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introducing human papillomavirus vaccines - questions remain.
    Paavonen J; Lehtinen M
    Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M; Dillner J
    J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine.
    Fraser C; Tomassini JE; Xi L; Golm G; Watson M; Giuliano AR; Barr E; Ault KA
    Vaccine; 2007 May; 25(21):4324-33. PubMed ID: 17445955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chapter 17: Second generation HPV vaccines to prevent cervical cancer.
    Schiller JT; Nardelli-Haefliger D
    Vaccine; 2006 Aug; 24 Suppl 3():S3/147-53. PubMed ID: 16950002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review.
    Ault KA
    Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S26-31. PubMed ID: 16729901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
    Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
    Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
    Block SL; Brown DR; Chatterjee A; Gold MA; Sings HL; Meibohm A; Dana A; Haupt RM; Barr E; Tamms GM; Zhou H; Reisinger KS
    Pediatr Infect Dis J; 2010 Feb; 29(2):95-101. PubMed ID: 19952863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
    Yancey AM; Pitlick JM; Forinash AB
    Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
    Dunne EF; Datta SD; E Markowitz L
    Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
    Villa LL
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing human papillomavirus vaccine efficacy and safety.
    Hendrix SL
    J Am Osteopath Assoc; 2008 Apr; 108(4 Suppl 2):S8-S12. PubMed ID: 18463363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
    Paavonen J;
    Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.